The inclusion of new entities and the deletion of outdated ones reflect ongoing research and clinical observations ... inhibitors, zanubrutinib and ibrutinib, for patients with relapsed or ...

Prelude Therapeutics (PRLD) Incorporated announced the presentation of the first interim clinical data from its ongoing open-label, dose-escalation trial of PRT2527, a potent and highly selective ...

A Peter Mac-led international clinical trial has shown adding an immunotherapy drug to the chemotherapy that patients receive ...

Pharmaceuticals presented updated azenosertib monotherapy clinical data from its ZN-c3-001, MAMMOTH and DENALI studies and ...

Results from DENALI Part 1b show an Objective Response Rate (ORR) of ~35% in response-evaluable, heavily-pretreated patients with Cyclin E1+ ...

Dr. Scott Kopetz discusses the BREAKWATER trial investigating Braftovi and Erbitux plus chemo in those with BRAF V600E+ ...

This clinical trial includes a dose escalation phase followed by an expansion phase, evaluating the potential of Lixumistat, an inhibitor targeting metabolism, in combination with gemcitabine and ...

One of the earliest proponents of evidence-based medicine, Professor David Sackett, wrote, “Good doctors use both individual ...

It can be viewed as encompassing preclinical research (for example, in cellular systems and animal models) and clinical research (for example, clinical trials). Spatial-Mux-seq adds to a growing ...

Jammu-Srinagar Vande Bharat: Launched as a part of India's 'Make in India' initiative, the Vande Bharat Express is India's first indigenous semi-high-speed train. (Image: PTI) Commercial ...

Pfizer has reported positive outcomes from the Phase III BREAKWATER trial of BRAFTOVI plus cetuximab and mFOLFOX6 for ...

The trial builds off the company’s previous Phase Ia/II trial that saw an estimated survival rate of 52.4% at 24 months in ...